Health Technology Assessment

32 Items

This section focuses on health technology assessment, economic evaluation, reimbursement, and policy, addressing the clinical, economic, and societal value of health technologies to support evidence‑based pricing, access, and sustainable healthcare decision‑making.

 

 

All Items

  • Evolution of treatments for hereditary angioedema in Italy: use of lanadelumab in clinical practice

    Marta Nugnes, Melania Dovizio, Melania Leogrande, Luca Degli Esposti
    13-19
    DOI: https://doi.org/10.33393/ao.2025.3468

  • Enhancing regulatory affairs in the market placing of new medical devices: how LLMs like ChatGPT may support and simplify processes

    Fabio Di Bello, Eliana Russo, Matteo Sartori
    77-88
    DOI: https://doi.org/10.33393/ao.2024.3302

  • An Activity-Based Costing model applied to the management process of patients with migraine at IRCCS Mondino Foundation

    Luca Degli Esposti, Alessandro Tabarroni, Valentina Perrone, Luisa Gervasio, Alberto Pinelli, Grazia Sances
    61-65
    DOI: https://doi.org/10.33393/ao.2024.3096

  • Innovation in the management of the breast cancer patient pathway: from correct identification to target therapies. Perspectives, opportunities and insights

    Vincenzo Adamo, Mario Airoldi, Gianni Amunni
    42-47
    DOI: https://doi.org/10.33393/ao.2024.3084

  • Using the Nephrology Referral Form in Italian primary care to improve the care pathway of patients with anemia or other complications related to chronic kidney disease: survey findings

    Giuseppe Pompilio, Francesca Pia Chiara Leone, Marco Gullì, Davide Integlia
    37-41
    DOI: https://doi.org/10.33393/ao.2024.3066

  • Economic evaluation of two therapeutic sequences in the first-line treatment of moderate to severe active ulcerative rectocolitis in Italy

    Patrizio Armeni, Elena Compagnucci , Gionata Fiorino, Vincenzo Lolli, Grazia Mazzone , Ambrogio Orlando, Mariabeatrice Principi, Roberto Ravasio, Fernando Rizzello, Edoardo Vincenzo Savarino, Francesca Tombari
    21-29
    DOI: https://doi.org/10.33393/ao.2024.2893

  • Early access according to Law 648: a review for the clinician

    Valentina Drago, Federica Giuffrida
    124-127
    DOI: https://doi.org/10.33393/ao.2023.2946

  • Brentuximab vedotin + AVD in cHL: cost impact on adverse events, toxicity, second malignancies, end-of-life and subsequent lines of therapy in Italy

    Chiara Vassallo, Beatrice Canali, Francesca Fiorentino, Paolo Morelli, Silvia Ripoli, Laura Fioravanti
    103-109
    DOI: https://doi.org/10.33393/ao.2023.2609

  • Refractory CMV infection in post-transplant phase: epidemiological framing in the Italian context, current patient management and unmet needs

    Marianna Morani, Fausto Baldanti, Fabio Ciceri, Franco Citterio, Mariano Ferraresso, Corrado Girmenia, Umberto Maggiore, Massimo Martino, Francesco Onida, Luciano Potena, Fabio Vistoli, Paolo Antonio Grossi
    97-102
    DOI: https://doi.org/10.33393/ao.2023.2564

  • Comments to “Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy”

    Ottavio Secchi, Andrea Franchi, Armando Lunello
    82-86
    DOI: https://doi.org/10.33393/ao.2023.2600

  • Cost-minimization analysis of HYQVIA® in the treatment of primary immunodeficiency disease (PID) and secondary immunodeficiency disease (SID) in Italy

    Roberto Ravasio, Silvia Ripoli
    69-77
    DOI: https://doi.org/10.33393/ao.2023.2584

  • Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy

    Roberto Ravasio, Raffaella Viti, Antonio Saverio Roscini
    13-21
    DOI: https://doi.org/10.33393/ao.2023.2515

  • Model for estimating the impact of healthcare costs in non-hospitalized Covid-19 patients treated with remdesivir

    Matteo Ruggeri, Alessandro Signorini, Silvia Caravaggio, Marco Falcone, Giovanni Di Perri
    114-121
    DOI: https://doi.org/10.33393/ao.2022.2473

  • Savings associated with therapeutic appropriateness for patients with relapsed refractory multiple myeloma and high cytogenetic risk diagnosed by FISH test

    Rossella Bitonti, Federica Demma, Massimiliano Rea, Gianluca Furneri
    105-111
    DOI: https://doi.org/10.33393/ao.2022.2447

  • Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor

    Roberto Ravasio, Holly Cranmer, Izzie Kearns , Raffaella Viti, Simone Corinti
    92-104
    DOI: https://doi.org/10.33393/ao.2022.2450

  • Emicizumab in hemophilia A with inhibitors: clinical and economic impact of its use in a Cuban patient

    Dunia Castillo-Gonzàles, Irianys Álvarez Sardiñas, Consuelo Macías Abraham, Alex G. Muñoz Bedoya
    83-86
    DOI: https://doi.org/10.33393/ao.2022.2438

  • Cost analysis comparison of rurioctocog alfa pegol compared to turoctocog alfa pegol in the prophylaxis of Haemophilia A in Italy

    Federica Demma, Pierpaola Arpa
    36-42
    DOI: https://doi.org/10.33393/ao.2022.2405

  • Economic impact of Enterosgel® in the hospital treatment of diarrhoeal syndromes associated with different disease conditions

    Roberto Ravasio, Paola Raimondo
    99-105
    DOI: https://doi.org/10.33393/ao.2021.2345

  • Brentuximab vedotin in adult patients with HL CD30+ at high risk of relapse or progression following ASCT: a cost-analysis in Italy

    Gian Luca Breschi, Federica Demma, Paolo Morelli, Maria De Francesco
    81-87
    DOI: https://doi.org/10.33393/ao.2021.2263

  • Orthopaedic device manufacturers’ perspective on MDR compliance

    Peter Fennema, Hassan Achakri
    34
    DOI: https://doi.org/10.33393/ao.2021.2280

  • Cost-effectiveness analysis with direct-acting antivirals in a cohort of HCV-infected inmates in Italy Analisi di costo-efficacia dei farmaci ad azione antivirale diretta nel trattamento dell’epatite cronica C nella popolazione carceraria italiana

    Roberto Ravasio, Luciano Lucania, Roberto Ranieri, Raquel Dominguez
    103-111
    DOI: https://doi.org/10.33393/ao.2020.2190

  • Time to reimbursement and negotiation condition in Italy for drugs approved by the European Medicines Agency during the period 2014-2019

    Mariangela Prada, Letizia Rossi, Matteo Mantovani
    89-94
    DOI: https://doi.org/10.33393/abtpn.2020.2184

  • Model for estimating the healthcare costs and capacity of intensive care units in Italy in the treatment of patients with COVID-19: remdesivir impact assessment

    Matteo Ruggeri, Alessandro Signorini, Carlo Drago, Francesco Rosiello, Marco Marchetti
    95-102
    DOI: https://doi.org/10.33393/abtpn.2020.2213

  • Socioeconomic impact of migraine in Italy: Results of a national survey

    Mihaela Nica, Delia Colombo, Roberto Ravasio, Carla Rognoni
    80-88
    DOI: https://doi.org/10.33393/abtpn.2020.2189

  • Economic evaluation of low-dose SKA cytokines in patients with rheumatoid arthritis in maintaining low disease activity or remission

    Roberto Ravasio, Alberto Migliore
    67-73
    DOI: https://doi.org/10.33393/abtpn.2020.2153
1-25 of 32